Trials / Completed
CompletedNCT01462890
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 927 (actual)
- Sponsor
- AGO Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.
Detailed description
Determination whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months
Conditions
- Genital Diseases, Female
- Ovarian Diseases
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bevacizumab | 15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44 |
| DRUG | Paclitaxel | 175 mg/m², iv on day 1 every 3 weeks for 6 cycles |
| DRUG | Carboplatin | AUC 5, iv on day 1 every 3 weeks for 6 cycles |
| OTHER | specialized pathology review (Germany only) | before randomization |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2020-12-31
- Completion
- 2021-12-01
- First posted
- 2011-11-01
- Last updated
- 2022-07-20
Locations
131 sites across 6 countries: Denmark, Finland, France, Germany, Norway, Sweden
Source: ClinicalTrials.gov record NCT01462890. Inclusion in this directory is not an endorsement.